TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00927290

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Pioglitazone, 45 mg QD (30 mg QD the first month)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 45 mg QD (30 mg QD the first month)
Study: NCT01547169

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: saline, taken twice per day for a 3 week duration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: 10IU of insulin detemir, administered intranasally twice per day for a 3 week duration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: 20IU insulin detemir, administered intranasally twice per day for a 3 week duration
Study: NCT00841568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-41061
Description: orally administered at 15 mg twice daily (morning and evening) for a maximum of 3 years.
Study: NCT03566355

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: curative proton therapy
Description: Patients who meet the selection criteria are selected, signed for consent, and treated with proton therapy alone at 7200 cGy / 15 fractions, 5 times a week for 3 weeks
Study: NCT00670670

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPP-ACP (GC Tooth Mousse)
Description: Calcium and phosphate

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPP-ACP (GC MI Paste Plus)
Description: Calcium, phosphate and fluoride
Study: NCT01022242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PXL01
Description: PXL01 is a synthetic peptide sequentially derived from human lactoferrin. PXL01 is formulated in a viscous solution of sodium hyaluronate. The drug product is administered locally between the flexor tendon and the tendon sheath and around the tendon sheath at a volume of 0.5 ml. Administration of the product is carried out after repair of the flexor tendon but before closure of the surgical wound.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a physiological sodium chloride solution, which is clear and colourless.
Study: NCT03819348

Intervention type: OTHER
Intervention: the multiple programs of antifungal therapy for HIV-negative host
Description: the multiple programs of antifungal therapy for HIV-negative host TSM were compared in terms of effect on clinical remission rate, effective rate, recurrence rate, mortality and toxic side effects on HIV-negative host TSM; their prognosis and recurrence indicators were clarified, and a therapeutic effect evaluation system was established, providing a standard treatment and diagnosis scheme for clinical practice; and simultaneously the positive rate of G and GM experiments in respect of TSM, Aspergillus and other fungi was identified to provide TSM with biological diagnostic indicators.
Study: NCT04178694

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non-invasive ventilation
Description: non-invasive ventilation will be performed on every subjects
Study: NCT00545727

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: Whole-foods, low glycemic index diet

Intervention type: OTHER
Group type: OTHER
Intervention: Standard diet
Description: Standard diet meeting American Diabetes Association guidelines
Study: NCT01556139

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spirotiger
Description: The Training group perform 20 sessions of a specific training with Spirotiger, a device allowing respiratory muscle training with isocapnic hyperpnea.~The setting is the following:~* volume/size of the breathing bag: 50% of the vital capacity (VC) and ventilation (VE= Tidal volume x respiratory rate) at 66% of the MVV aiming to reach 15 minutes of training without breaks. During the initial sessions, the patient can interrupt training every 5 minutes and recover.~* increase in training: after 15 minutes of exercise VE is increased up to 75% of the MVV through modification of the volume of breathing bag or respiratory rate.~At the end of 15 minutes of exercise, further increases in ventilation are 10% of each previous step.
Study: NCT04080947

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: patients received matching-image placebo once daily at bedtime for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast group
Description: patients received montelukast (10-mg chewable tablet) once daily at bedtime for 12 weeks.
Study: NCT01820364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGX818
Description: BRAF inhibitor. LGX818 was administered QD orally on a daily schedule (21-day cycles) as a flat-fixed dose and not by body weight or body surface area. LGX818 100 mg capsules and 50 mg capsules.
Study: NCT03418129

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Neuromodulatory intervention for pain management

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Description: Neuromodulatory intervention for pain management

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Relaxation
Description: Neuromodulatory intervention for pain management
Study: NCT00851539

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video
Description: Behavioral Intervention Video
Study: NCT04960982

Intervention type: DIAGNOSTIC_TEST
Intervention: blood test
Description: blood sample is taken in first, second and third trimester of pregnancy

Intervention type: DIAGNOSTIC_TEST
Intervention: blood test
Description: blood sample is taken in first, second and third trimester of pregnancy

Intervention type: DIAGNOSTIC_TEST
Intervention: blood test
Description: blood sample is taken in first, second and third trimester of pregnancy
Study: NCT03300674

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone
Description: Hydromorphone intravenous infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine intravenous infusion
Study: NCT03755895

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: formal hypnosis
Description: patients will have brachytherapy detachment under Kalinox and formal hypnosis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kalinox
Description: patients will have brachytherapy detachment under Kalinox

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kalinox
Description: patients will have brachytherapy detachment under Kalinox
Study: NCT03521024

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: poly ether ketone ketone
Description: Polyetherketoneketone (PEKK) forms a group of high-performance thermoplastic polymers. PEKK shows excellent biocompatibility and exhibits outstanding properties such as high wear resistance and high compressive (246 MPa), flexural (5.0GPa), and tensile strengths (115 MPa). The material is lightweight, allows shock absorption, and can be veneered with various commercially available dental materials

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: poly ether ketone ketone
Description: Polyetherketoneketone (PEKK) forms a group of high-performance thermoplastic polymers. PEKK shows excellent biocompatibility and exhibits outstanding properties such as high wear resistance and high compressive (246 MPa), flexural (5.0GPa), and tensile strengths (115 MPa). The material is lightweight, allows shock absorption, and can be veneered with various commercially available dental materials

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: lithium disilicate
Description: well documented in the literatures as successful restoration modality.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lithium disilicate
Description: well documented in the literatures as successful restoration modality.
Study: NCT00547170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline pre-operatively
Description: Two capsules of Doxycycline 100 mg before vacuum aspiration Placebo 100 mg twice daily for 5 days after vacuum aspiration (appearance of capsules is the same for both groups)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline post-operatively
Description: Two capsules of placebo 100 mg before vacuum aspiration Doxycycline 100 mg twice daily for 5 days after vacuum aspiration (appearance of capsules is the same for both groups)
Study: NCT02032563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: intravenous injection of 0.25mg/kg Indocyanine Green just before the surgery
Study: NCT02227602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mango polyphenolics
Description: Frozen mango pack will be provided (200\~400g per day).
Study: NCT00788281

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic surgery
Description: surgery would be performed by laparoscope

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open surgery
Description: surgery would be performed by traditional surgery.
Study: NCT02198703

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics bacterial strains

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04159220

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clamping of the ventilator endotracheal tube
Description: The transport will be released in accordance with SFAR SRLF guideline. Before each disconnection from ventilator endotracheal tube will be clamped.
Study: NCT04918199

Intervention type: DEVICE
Intervention: Computer based assessment (iBox)
Description: Individual allograft survival probabilities of death censored allograft survival seven years after the time of risk evaluation, computed using the iBox (NCT03474003), a qualified prognostication system designed to predict long term allograft survival up to seven years after evaluation.

Intervention type: OTHER
Intervention: Physician assessement
Description: Based on anonymized electronic health records, physicians have to determine a percentage of death censored allograft survival seven years after the time of risk evaluation,
Study: NCT03295370

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrical Stimulation
Description: A needle is placed near accessory spinal nerve; electrical burst stimulation for 12 minutes, 10 Hz;

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Electrical Stimulation
Description: A needle is placed near accessory spinal nerve; electrical burst stimulation for 12 minutes, 10 Hz;
Study: NCT01651624

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Invitation to screening

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Invitation to screening

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Invitation to screening

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Invitation to screening
Study: NCT00841789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: etanercept 0.8 mg/kg subcutaneously (max 50 mg) given three times, once a week for three weeks starting at initial diagnosis.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 0.8 mg/kg subcutaneously (max 50 mg) given three times, once a week for three weeks starting at initial diagnosis.
Study: NCT01857284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tauroursodeoxycholic Acid Capsules
Description: 250mg.tid.po

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ursodeoxycholic Acid Capsules
Description: 250mg.tid.po
Study: NCT00825162

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL Limited Influenza Virus Vaccine
Description: Single or two-vaccination regimen (0.25mL)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL Limited Influenza Virus Vaccine
Description: Single or two-vaccination regimen (0.5mL)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL Limited Influenza Virus Vaccine
Description: Single vaccination regimen (0.5mL)
Study: NCT04227509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: normal saline will be administered as a 30 minute IV infusion every 3 weeks.
Study: NCT04443543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine (Xeloda) Pharmacogenetic Test Reagents
Description: CRT: 625mg/m2 bid Monday-Friday per week XELIRI: 1000mg/m2 bid d1-14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine (Xeloda) Pharmacogenetic Test Reagents
Description: CRT: 625mg/m2 bid Monday-Friday per week XELIRI: 1000mg/m2 bid d1-14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: CRT:80mg/m2 (UGT1A1\*28 6/6) or 65mg/m2 (UGT1A1\*28 6/7) XELIRI: 200mg/m2 bid d1 FOLFIRINOX: 150mg/m2 d1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: CRT:80mg/m2 (UGT1A1\*28 6/6) or 65mg/m2 (UGT1A1\*28 6/7) XELIRI: 200mg/m2 bid d1 FOLFIRINOX: 150mg/m2 d1

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: Pelvic Radiation: 50Gy/25Fx

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: Pelvic Radiation: 50Gy/25Fx

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: FOLFIRINOX: 85mg/m2 d1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5Fluorouracil
Description: FOLFIRINOX: 400mg/m2 iv d1bolus, 2400mg/m2 ivgtt 46h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200mg iv
Study: NCT05016115

Intervention type: BEHAVIORAL
Intervention: survey
Description: The Turkish reworded student version of the Jefferson scale of physician empathy was used. Empathy scores were compared related to study years and gender.
Study: NCT03263962

Intervention type: DRUG
Intervention: Canrenone
Description: Evaluation of canrenone therapy in patients with CHF
Study: NCT04220541

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor learning based exercise
Description: Symptomatic exercise

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motor learning based exercise
Description: Symptomatic exercise
Study: NCT00874510

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mandatory Naps
Description: As above, interns on extended duty overnight call shifts will be required to transfer cell phones and cross-coverage responsibilities to night float residents for a 5 hour period each night they are on call. For Year 2, interns will nap in shifts, instead of concurrently, with the first nap shift between 12am-3am and the second shift between 3am-6am
Study: NCT03658265

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 7 days SIE plus 4 weeks PRE
Description: Shoulder isotonic exercise (SIE)：exercise methods for shortening and relaxing the muscles around the shoulder joint.~Progressive resistance exercise (PRE)：A training method that gradually increases the resistance, which will increase the muscle capacity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 7 days SIE plus 3 weeks PRE
Description: Shoulder isotonic exercise (SIE)：exercise methods for shortening and relaxing the muscles around the shoulder joint.~Progressive resistance exercise (PRE)：A training method that gradually increases the resistance, which will increase the muscle capacity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3 days SIE plus 4 weeks PRE
Description: Shoulder isotonic exercise (SIE)：exercise methods for shortening and relaxing the muscles around the shoulder joint.~Progressive resistance exercise (PRE)：A training method that gradually increases the resistance, which will increase the muscle capacity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3 days SIE plus 3 weeks PRE
Description: Shoulder isotonic exercise (SIE)：exercise methods for shortening and relaxing the muscles around the shoulder joint.~Progressive resistance exercise (PRE)：A training method that gradually increases the resistance, which will increase the muscle capacity.
Study: NCT01391286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimatoprost solution 0.03%
Description: One drop of bimatoprost solution 0.03% applied along each upper eyelid margin once daily in the evening for 4 months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: bimatoprost vehicle solution
Description: One drop of bimatoprost vehicle solution applied along each upper eyelid margin once daily in the evening for 4 months.
Study: NCT04049838

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: postoperative analgesia for lower abdominal surgery in children
Description: compare lateral and posterior approaches of trannsversus abdominis plane block for analgesia after lower abdominal surgery in children

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: postoperative analgesia for lower abdominal surgery in children
Description: compare lateral and posterior approaches of trannsversus abdominis plane block for analgesia after lower abdominal surgery in children

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: postoperative analgesia for lower abdominal surgery in children
Description: compare lateral and posterior approaches of trannsversus abdominis plane block for analgesia after lower abdominal surgery in children
Study: NCT00939783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimebon
Description: Tablet for oral administration
Study: NCT00964535

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide and formoterol 200/6 microg
Description: 2 inhalations as a single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: budesonide and formoterol 200/6 microg
Description: 2 inhalations as a single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide and formoterol 200/6 microg
Description: 2 inhalations as a single dose with the concurrent charcoal blockage

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: budesonide and formoterol 200/6 microg
Description: 2 inhalations as a single dose with the concurrent charcoal blockage
Study: NCT00409084

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic variceal band ligation
Description: endoscopic variceal band ligation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: endoscopic variceal band ligation
Description: endoscopic variceal band ligation
Study: NCT01783275

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: 12 weeks of aerobic exercise with weight maintenance
Study: NCT03672409

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Intervention in knowledge
Description: The knowledge intervention will be done through four group learning sessions with the objective of significantly increasing diabetes knowledge in health professionals.~The learning sessions will be carried out weekly in a period of 4 weeks, with a duration of 60 minutes per session. In addition, two sessions will be held for the evaluation of pre and post intervention knowledge. The learning sessions consist in the diagnosis, evaluation, complications and comorbidities, pharmacological treatment and nutrition in type 2 diabetes.
Study: NCT01298752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mapracorat
Description: Mapracorat ophthalmic suspension 3%, one drop in post-operative study eye once daily (QD) for 2 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle of mapracorat ophthalmic suspension, one drop in post-operative study eye once daily (QD) for 2 weeks.
Study: NCT01664559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Ketorolac 30mg intramuscular injection, 1cc volume

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Placebo arm, 1cc of normal saline, 0.9%, intramuscular injection
Study: NCT02895880

Intervention type: BEHAVIORAL
Intervention: usual care
Description: In order to characterize the content of and variation in usual care, the first 25 patients enrolled in the study will complete a post-visit questionnaire that asks what their doctor told them (if anything) about their risk of cardiovascular disease, risk reduction and statins specifically, and how this information was presented

Intervention type: BEHAVIORAL
Intervention: statin communication tool
Description: The Statin Choice decision aid uses icon arrays to communicate the expected benefits of statins. This modified risk communication tool will maintain the components of the validated original. The adapted paper-based risk communication tool will describe modified risk profiles applicable to the survivors at increased risk for cardiac disease due to chest irradiation.
Study: NCT03741114

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Foley's Catheter
Description: patients managed by Intrauterine Inflated Foley's Catheter Balloon after delivery of the fetus.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Foley's Catheter
Description: patients managed by Intrauterine Inflated Foley's Catheter Balloon after delivery of the fetus.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TA
Description: patients received 1 gm tranexamic acid intravenous just before skin incision in 100 ml saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: patients received 100 ml saline just before skin incision
Study: NCT00868062

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Succinylated gelatine, 40g/L, (Gelofusine - B Braun)
Description: 1 litre infusion following induction of anaesthesia
Study: NCT03113656

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weighted Blanket
Description: Weighted blanket placed on infant for 30 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weighted Blanket
Description: Weighted blanket placed on infant for 30 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-Weighted Blanket
Description: Non-Weighted blanket placed on infant for 30 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-Weighted Blanket
Description: Non-Weighted blanket placed on infant for 30 minutes
Study: NCT01833286

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE+RFA
Description: TACE first, followed by RFA within 2 months

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: re-resection
Description: repeat hepatectomy for recurrent small HCC